Skip to product information
1 of 1

MULTI SCIENCES

Human G-CSF ELISA Kit For Protein Quantification

Human G-CSF ELISA Kit For Protein Quantification

SKU:EK169

Regular price Send Inquiry
Regular price Sale price Send Inquiry
Sale Sold out
View full details

Product Details

Human G-CSF ELISA Kit For Protein Quantification

Brand MultiSciences
CatNum 70-EK169
Product Name Human G-CSF ELISA Kit
Customs Name Human G-CSF ELISA Kit
Application ELISA
Reactivity Human
Assay Type Sandwich ELISA
Suitable Sample Type serum, plasma, cell culture supernates
Format 96-well strip plate
Storage 4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened)
Shipping Condition 4℃
Sample Volume 50 μl
Sensitivity 6.04 pg/ml
Standard Curve Range 31.25 - 2000 pg/ml
Spike Recovery Range 88 % - 116 %
Mean Spike Recovery 1.09
CV of Intra plate 7.4 % - 7.8 %
CV of Inter plate 8.3 % - 12.6 %
Components 96-well polystyrene microplate coated with a monoclonal antibody against G-CSF
Human G-CSF Standard, lyophilized
G-CSF Detect Antibody
Standard Diluent
Streptavidin-HRP
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
Wash Buffer (20×)
Plate Covers
Describtion This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human G-CSF. The Human G-CSF ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Granulocyte-colony stimulating factor (G-CSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by endothelium, macrophages, and a number of other immune cells. G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. In oncology and hematology, a recombinant form of G-CSF is used with certain cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens.